IPSC Transfer Approved by Nasdaq; Reverse Split Possible to Cure $1 Bid-Price Deficiency

Rhea-AI Filing Summary

Century Therapeutics, Inc. received a deficiency letter from Nasdaq after its closing bid price fell below the $1.00 minimum over the last 30 consecutive business days, triggering a 180-day compliance period that ran to August 26, 2025. Nasdaq determined the company otherwise met market value and initial listing requirements for The Nasdaq Capital Market and accepted the company's plan to cure the deficiency, including a possible reverse stock split. On August 27, 2025 Nasdaq approved Century's transfer from The Nasdaq Global Select Market to The Nasdaq Capital Market and the company's common stock continues to trade under the symbol IPSC. The filing notes the transfer became effective at the opening of business on August 27, 2025, although one date in the text appears truncated.

Positive

• Nasdaq approved transfer to The Nasdaq Capital Market, preserving continuous trading under the existing ticker IPSC
• Company met market value of publicly held shares and other initial listing requirements for The Nasdaq Capital Market aside from the bid-price rule

Negative

• Deficiency letter received due to the closing bid price being below the $1.00 minimum for 30 consecutive business days
• Company may need to effect a reverse stock split to regain compliance with Nasdaq's bid-price requirement

Insights

Corporate Governance Expert

TL;DR: Transfer to the Nasdaq Capital Market resolves listing status while signaling governance and market-price concerns that management must address.

The transfer reflects Nasdaq's view that Century meets several listing standards but not the $1.00 bid-price rule. Moving to The Nasdaq Capital Market preserves continuous trading under the same ticker and avoids suspension or delisting while giving the company a path to regain compliance, including a potential reverse split. From a governance standpoint, management must communicate a clear remediation plan and timeline to shareholders to mitigate uncertainty. The action is procedural but highlights stock-price weakness that may affect investor perception and liquidity.

Securities Analyst

TL;DR: Nasdaq approved relocation to the Capital Market after a bid-price deficiency; trading continues as IPSC but fundamentals not disclosed here.

The filing documents a technical noncompliance tied solely to the 30-day closing bid below $1.00 and confirms Nasdaq granted a 180-day cure period ending August 26, 2025. Approval to transfer markets preserves listing and trading continuity, reducing immediate market disruption risk. The company signaled willingness to use a reverse split if needed, which would be a shareholder-dilutive or share-consolidating action depending on execution. This disclosure is procedural and lacks operational or financial detail that would allow assessment of business performance.

8-K Event Classification

Item 3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

1 item

Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing Securities

The company received a delisting notice or transferred its listing to a different exchange.

Understanding 8-K Material Events →

false 0001850119 0001850119 2025-08-27 2025-08-27 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 27, 2025

Century Therapeutics, Inc.

(Exact name of registrant as specified in its charter)

Delaware		001-40498		84-2040295
(State or other jurisdiction of incorporation or organization)		(Commission File Number)		(I.R.S. Employer Identification No.)

25 North 38th Street, 11th Floor Philadelphia, Pennsylvania		19104
(Address of principal executive offices)		(Zip Code)

Registrant’s telephone number, including area code: (267) 817-5790

Not Applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

¨	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of Each Class		Trading Symbol		Name of Exchange on Which Registered
Common Stock, par value $0.0001 per share		IPSC		Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company x

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.

On February 26, 2025, Century Therapeutics, Inc. (the “Company”) received a deficiency letter from the Nasdaq Listing Qualifications Staff (“Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that based on the closing bid price for the last 30 consecutive business days, the Company was not in compliance with the $1.00 minimum bid price requirement for continued listing on The Nasdaq Global Select Market, as set forth in Nasdaq Listing Rule 5450(a)(1) (the “Bid Price Rule”). In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company was provided a period of 180 calendar days, or until August 26, 2025 (the “Initial Compliance Date”), to regain compliance with the Bid Price Rule.

The Company did not regain compliance with the Bid Price Rule by the Initial Compliance Date. On August 27, 2025, Nasdaq notified the Company that it had granted the Company an additional 180 calendar day period, or until February 23, 2026 (the “Extended Compliance Date”), to regain compliance with the Bid Price Rule. Nasdaq’s determination was based on, among other things, (1) the Company meeting the continued listing requirement for market value of publicly held shares and all other initial listing requirements for The Nasdaq Capital Market, with the exception of the Bid Price Rule, and (2) the Company’s written notice of its intention to cure the deficiency by effecting a reverse stock split, if necessary. On August 27, 2025, Nasdaq approved the Company’s transfer from The Nasdaq Global Select Market to The Nasdaq Capital Market. This transfer became effective at the opening of business on August 27, 202 and the Company’s common stock continues to trade under the symbol “IPSC.” The Nasdaq Capital Market is a continuous trading market that operates in substantially the same manner as The Nasdaq Global Select Market, and listed companies must meet certain financial requirements and comply with Nasdaq’s corporate governance requirements.

If, at any time before the Extended Compliance Date, the closing bid price for the Company’s common stock is at least $1.00 per share for a minimum of 10 consecutive business days as required under the Bid Price Rule, Nasdaq will provide written notification to the Company that it complies with the Bid Price Rule.

The Company intends to continue to monitor the closing bid price of its common stock and will consider available options, including a reverse stock split, to regain compliance with the Bid Price Rule. There can be no assurance that the Company will be able to regain compliance with the Bid Price Rule or will otherwise be in compliance with other Nasdaq listing criteria.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

CENTURY THERAPEUTICS, INC.
By:	/s/ Brent Pfeiffenberger, Pharm.D.
Name:	Brent Pfeiffenberger, Pharm.D.
Title:	President and Chief Executive Officer

Date: August 29, 2025

FAQ

Why did Nasdaq issue a deficiency letter to Century Therapeutics (IPSC)?

Nasdaq notified the company because the closing bid price was below $1.00 for the last 30 consecutive business days, violating the minimum bid-price requirement.

What deadline was Century given to regain compliance with Nasdaq's bid-price rule?

The company was given a 180-calendar-day period to regain compliance, which ran until August 26, 2025.

Did Nasdaq delist Century Therapeutics after the deficiency?

No. Nasdaq approved Century's transfer to The Nasdaq Capital Market, and the company's common stock continues to trade as IPSC.

Will Century Therapeutics change its ticker symbol after the transfer?

No. The filing states the company's common stock continues to trade under the symbol IPSC.

What remedial action did the company indicate it might take to cure the deficiency?

The company indicated in writing that it may cure the deficiency by effecting a reverse stock split, if necessary.